Novo Nordisk is expanding its tabletting facility in Monksland, Athlone, Ireland with a 432 million euro ($372.5 million) ...

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to produce its "current and future" GLP-1 agonist-based therapies for diseases ...

Too early to say if €400m investment will result in more permanent jobs for the county - News - Roscommon Herald ...

Novo Nordisk has announced it will invest 432m euros in its facility in Ireland. The tabletting facility, in Monksland, Athlone, will provide significant additional manufacturing capacity for current ...

Novo said the investment, which is via an upgrade and retrofitting of the existing facility, will enhance its ability to manufacture oral GLP-1RAs. Credit: JHVEPhoto/Shutterstock.com Novo Nordisk has ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Novo Nordisk has entered a ...